tbuckley/cabot-search huggingface dataset:
Abstract 89: Pin1 suppresses androgen receptor activity
Authors: Travis Van der Steen, Haojie Huang, Donald Tindall
Journal: Cancer Research (2015)

Abstract Reactivation of the androgen receptor (AR) is the hallmark of prostate cancer (PCa) progression to the castration resistant prostate cancer (CRPC) phenotype. Currently, treatment for CRPC strives to impede the full-length AR (AR-FL) from becoming activated through targeting the ligand binding domain (LBD) via androgen deprivation therapy or treatment with antiandrogens. However, these options can give rise to AR-variants (AR-Vs) that lack the LBD and are unresponsive to treatment. Therefore, targeting the N-terminus of AR, which is conserved between AR-FL and AR-Vs, is critical for identifying new treatment options. Phosphorylation of serine 81 (AR-pS81) in the N-terminus of AR is critical for AR activation, stability and recruitment to the chromatin. Similar phosphorylation sites can be observed in the N-terminus of both AR-FL and AR-Vs. Expression of Pin1, a proline isomerase, exhibits a strong correlation with progression and relapse of PCa. Also, suppression of Pin1 in PCa decreases cell proliferation rates, suggesting that Pin1 may play a pivotal role in PCa progression. Pin1 isomerizes proline residues from trans to cis when the adjacent serine/threonine residue is phosphorylated. Dephosphorylation by phosphatases occurs when a pS-P motif is in the trans conformation. Therefore, Pin1 isomerization of AR pS81-P82 from trans to cis could prevent dephosphorylation and result in constitutive or enhanced AR activity. Stable cell lines with Pin1 knockdown were generated via shRNA targeting the 5′ UTR of Pin1 that express either AR-FL and/or AR-Vs. Pin1 knockdown was confirmed by western blots, and AR activity was monitored by expression of several AR regulated genes. Additionally, AR recruitment to chromatin was assayed by ChIP and Re-Chip. Loss of Pin1 resulted in a 60% reduction of endogenous PSA expression, and AR was unable to induce PSA expression when treated with androgens. However, suppression of AR activity was not due to decreased recruitment of AR to chromatin. Phosphorylation of AR-pS81 was decreased by loss of Pin1, while protein stability and mRNA expression was not altered. These data suggest that Pin1 may play a critical role in regulating the transcriptional activity of AR by altering the accessibility of AR to interact with transcriptional machinery needed to maintain AR activity. (Funding for this project was provided by the T.J. Martell Foundation). Citation Format: Travis Van der Steen, Haojie Huang, Donald Tindall. Pin1 suppresses androgen receptor activity. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 89. doi:10.1158/1538-7445.AM2015-89
Abstract P101: Hypertension in Pregnancy and Risk of Hypertension in Later Life: The Bogalusa Heart Study
Authors: Shengxu Li, Xu Xiong, Camilo Fernandez, Wei Chen, Sathanur R Srinivasan, Gerald S Berenson
Journal: Circulation (2014)

Background: Few studies have examined whether hypertension in pregnancy imposes long-term cardiovascular risk compared to a normal pregnancy. The objective of this study was to examine if previous history of hypertension in pregnancy is a risk for hypertension after pregnancy. Methods: A case-control analysis was performed using the Bogalusa Heart Study database. Cases were defined as women whose systolic blood pressure ≥140 mmHg or diastolic ≥ 90 mmHg, or having hypertension treatment. Controls were defined as women with normal blood pressure. After exclusions, 604 women (67% white and 33% black, aged 32-44 years) were included for analysis. Univariable and multivariable logistic regression were used to estimate the odds ratio (OR) and 95% confidence interval (CI). Results: The prevalence of hypertension in women was 12.1% (73/604). Hypertensive women had higher proportion of previous history of hypertension in pregnancy (25/73, 34%) than normotensive controls (83/531, 13.7%), with an OR of 2.81 (95% CI: 1.64-4.81). After adjustment for age, race, body mass index and smoking, adjusted OR (aOR) of having previous history of hypertension in pregnancy for developing hypertension later was 1.36 (1.00-3.75). In addition, age, black ethnicity and body mass index were associated with hypertension, with aORs of 1.16 (1.09-1.25), 3.73 (2.13-6.52), and 1.09 (1.05-1.13), respectively. Conclusions: Hypertension in pregnancy may be associated with an increased risk of hypertension in later life. Further studies are needed to separate the effect of pregnancy-induced hypertension and pre-exiting chronic hypertension on the subsequent risk of hypertension later in life.
SUBACUTE BACTERIAL ENDARTERITIS COMPLICATING PATENT DUCTUS ARTERIOSUS: CASE REPORT WITH RECOVERY FOLLOWING SULFAPYRIDINE-HEPARIN THERAPY
Authors: William A. Winn, Clara L. Hughes, Jewell M. Sanders
Journal: Annals of Internal Medicine (1943)

Case Reports1 February 1943SUBACUTE BACTERIAL ENDARTERITIS COMPLICATING PATENT DUCTUS ARTERIOSUS: CASE REPORT WITH RECOVERY FOLLOWING SULFAPYRIDINE-HEPARIN THERAPYWILLIAM A. WINN, M.D., CLARA L. HUGHES, M.D., JEWELL M. SANDERS, M.D.WILLIAM A. WINN, M.D.Search for more papers by this author, CLARA L. HUGHES, M.D.Search for more papers by this author, JEWELL M. SANDERS, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-18-2-242 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe following case report of recovery from subacute bacterial endarteritis is presented because it marks the successful application of the treatment of this usually fatal infection by combined sulfapyridine and heparin therapy. The first announcement of this ingenious combination treatment was made by Kelson and White in 1939.1With the publication of further controlled studies2a definite feeling of optimism begins to appear in the medical attitude toward the unfortunate patient afflicted with an endocardial or endarterial infection due toStreptococcus viridans(alpha type). In the case herein reported there was the further factor of a tuberculous infection manifested by...Bibliography1. KELSONWHITE SRPD: A new method of treatment of subacute bacterial endocarditis, Jr. Am. Med. Assoc., 1939, cxiii, 1700. Google Scholar2. LEACHFAULKNER CEJM: Chemotherapy and heparin in subacute bacterial endocarditis, Jr. Am. Med. Assoc., 1941, cxvii, 1345. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Springville, California*Received for publication December 16, 1941.From Tulare-Kings Counties Joint Tuberculosis Hospital. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byFour great coccidioidomycologists: William Ophuls (1871–1933), Myrnie Gifford (1892–1966), Charles Edward Smith (1904–1967) and William A. Winn (1903–1967)William A. Winn: Some Recollections about a Great Clinician, a Great Scholar, and a Good FriendThe Treatment of Patent Ductus Arteriosus 1 February 1943Volume 18, Issue 2Page: 242-250KeywordsEmotionsHeparinPatent ductus arteriosusStreptococcal infectionsStreptococcus ePublished: 1 December 2008 Issue Published: 1 February 1943 PDF downloadLoading ...
Abstract MP86: Effects of Immediate Blood Pressure Reduction on Death and Major Disability in Acute Ischemic Stroke Patients by History of Hypertension and Use of Antihypertensive Medications
Authors: Tan Xu, Yonghong Zhang, Yingxian Sun, Chung-Shiuan Chen, Jing Chen, Jiang He
Journal: Circulation (2015)

Introduction: The effects of blood pressure (BP) reduction on clinical outcomes among acute stroke patient remain uncertain. Hypothesis: We tested the effects of immediate BP reduction on death and major disability at 14 days or hospital discharge and 3-month follow-up in acute ischemic stroke patients with and without a previous history of hypertension or use of antihypertensive medications. Methods: The China Antihypertensive Trial in Acute Ischemic Stroke (CATIS) randomly assigned patients with ischemic stroke within 48 hours of onset and elevated systolic BP (SBP) to receive antihypertensive treatment (N=2,038) or to discontinue all antihypertensive medications (N=2,033) during hospitalization. Randomization was stratified by participating hospitals and use of antihypertensive medications. Study outcomes were assessed at 14 days or hospital discharge and 3-month post-treatment follow-up. The primary outcome was death and major disability (modified Rankin Scale score≥3), and secondary outcomes included recurrent stroke and vascular events. Results: Mean SBP was reduced 12.7% in the treatment group and 7.2% in the control group within 24 hours after randomization (P&lt;0.001). Mean SBP was 137.3 mmHg in the treatment group and 146.5 in the control group at day 7 after randomization (P&lt;0.001). At 14 days or hospital discharge, the primary and secondary outcomes were not significantly different between the treatment and control groups by subgroups. At the 3-month follow-up, recurrent stroke was significantly reduced in the antihypertensive treatment group among patients with a history of hypertension (odds ratio 0.43, 95% CI 0.24-0.75, P=0.003) and among patients with a history of use of antihypertensive medications (odds ratio 0.41, 95% CI 0.20-0.84, P=0.01). All-cause mortality (odds ratio 2.84, 95% CI 1.11-7.27, P=0.03) was increased among patients without a history of hypertension. Conclusion: Immediate BP reduction lowers recurrent stroke among acute ischemic stroke patients with a previous history of hypertension or use of antihypertensive medications at 3 months. On the other hand, BP reduction increases all-cause mortality among patients without a history of hypertension.
Platelet geometry sensing spatially regulates α-granule secretion to enable matrix self-deposition
Authors: Yumiko Sakurai, Jennifer L. Fitch-Tewfik, Yongzhi Qiu, Byungwook Ahn, David R. Myers, Reginald Tran, Meredith E. Fay, Lingmei Ding, Paul W. Spearman, Alan D. Michelson, Robert Flaumenhaft, Wilbur A. Lam
Journal: Blood (2015)
Food Infections and Food Intoxications.
Authors: Samuel Reed Damon
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transition from Paediatric Clinic to the Adult Service
Authors: Richard E Appleton
Journal: Journal of the Royal Society of Medicine (2001)

Adolescence is a challenging, often traumatic but fascinating time of life whether or not it is accompanied by a chronic medical disorder such as diabetes, cystic fibrosis, arthritis—or epilepsy1,2,3, a condition which is in fact more common than the three preceding disorders cited by Professor David in his somewhat pessimistic editorial (August 2001 JRSM, pp. 373-374).

In 1991 a specific ‘hand-over’ or transition clinic for teenagers with epilepsy was established in Liverpool which is supervised jointly by a paediatric and an adult neurologist (both of whom have a particular interest in epilepsy) together with a nurse specialist in epilepsy. The primary objectives of this teenager clinic are to address the unique needs and concerns of this age group and, importantly, to facilitate a smooth hand-over of specialist epilepsy care from paediatric to adult services4. The success of this clinic—as assessed by both the teenagers themselves (who have a ‘did not attend clinic’ rate of < 3%)—and the development of other similar units throughout the UK and the rest of Europe, would suggest that this approach is generally regarded as a ‘model’ service. Undoubtedly, the success of this service is largely dependent on demonstrating a clear commitment to the young people, the philosophy and personalities of the clinic staff and the teenagers themselves.

In Liverpool, and for teenagers with epilepsy, the future is bright.
Injunction Affecting Abbott's in Vitro Test Devices
Authors: Jane E. Henney
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 863: Clinical significance of mucinous production in rectal cancer after preoperative chemoradiotherapy
Authors: Kensuke Kaneko
Journal: Cancer Research (2014)

Abstract Background: Mucinous adenocarcinoma (MA) is a relatively rare histological subtype of colorectal cancer, in which more than 50% of the tumor is occupied by extracellular mucin. MA has been reported to be associated with poor response to neoadjuvant chemoradiotherapy (CRT), but the prognostic significance still remains to be evaluated. Here, we aimed to analyze the prognostic significance of mucin production in the response of rectal cancer to neoadjuvant CRT. Methods: The medical records of 141 consecutive patients receiving rectal resection after neoadjuvant CRT for the treatment of rectal cancer at our institution, in the period between October 2003 and December 2012, were retrospectively reviewed. For the histological evaluation, Hematoxylin-Eosin (HE) and Periodic Acid Schiff/Alcian Blue (PAS/AB) stainings were used. Mucin production was evaluated according to the proportion of the tumor area occupied by extracellular mucin, and cases were sorted, according to the mucin occupancy rate, into three groups, namely, low (0 - 5%), medium (5 - 25%) and high (&amp;gt;25%). Results: The number of patients in the low, medium and high mucin rate groups was 89 (63.1%), 28 (19.9%) and 24 (17.0%), respectively. Only advanced tumor stage out of histological features had a significant correlation with the high mucin rate group. Compared to the low mucin rate group, patients in the high group had a worse prognosis in disease free survival, and also a worse prognosis in distant recurrence free survival, compared to the medium group, while no significant difference was observed among the three groups in overall and local recurrence-free survivals. Multivariate analysis showed that the high mucin rate group had an independent association with shorter disease-free survival, and those advanced stage tumors (T3 and T4) with a high mucin rate had an independent association with shorter distant recurrence-free survival. Conclusion: Mucinous production in rectal cancer may be associated with resistance to neoadjuvant CRT. Thus, careful histological analysis for the presence of extracellular mucin should be indicated for rectal patients receiving neoadjuvant CRT, and those cases with high mucin rate (&amp;gt; 25% mucinous component) should be closely followed-up. Citation Format: Kensuke Kaneko. Clinical significance of mucinous production in rectal cancer after preoperative chemoradiotherapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 863. doi:10.1158/1538-7445.AM2014-863
Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins
Authors: Marina Konopleva, Ana M. Tari, Zeev Estrov, David Harris, Zhong Xie, Shourong Zhao, Gabriel López-Berestein, Michael Andreeff
Journal: Blood (2000)
NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway
Authors: Masaki Terabe, So Matsui, Nancy Noben-Trauth, Hangjiong Chen, Cynthia Watson, Debra D. Donaldson, David P. Carbone, William E. Paul, Jay A. Berzofsky
Journal: Nature Immunology (2000)
Abstract OT3-1-06: A phase 2 single-arm study to evaluate the clinical activity, safety and tolerability of enzalutamide (ENZA) with trastuzumab in patients with advanced human growth factor receptor 2 (HER2)-positive breast cancer
Authors: Maureen E Trudeau, Eric Winer, Joyce L Steinberg, Maggie Liosatos, Srinivasu Poondru, Michael Dydo, Yun Zhou, Michael Westphal, Amy C Peterson, William Gradishar
Journal: Cancer Research (2015)

Abstract Background Androgen receptor (AR) expression is observed in ∼60% of patients (pts) with HER2+ breast cancer1. In vitro, ENZA inhibits proliferation of AR+/HER2+ cell lines and enhances the activity of trastuzumab. ENZA also inhibits proliferation of trastuzumab resistant HER2 positive cells2. Methods Any amount of AR expression (local or central) is allowed, submission of tissue is mandatory. Patients must have measurable disease per RECIST 1.1, and have received 1 to 4 prior lines of anti-HER2 therapy in the advanced / metastatic setting. Brain imaging is required to exclude patients with CNS metastases. Pts with a seizure history are excluded. Women with metastatic or locally advanced HER2+, AR+, and ER-/PgR- breast cancer will receive daily ENZA (160 mg) continuously and trastuzumab (6 mg/kg) administered every 21 days, until disease progression (NCT02091960). The primary endpoint (EP) is clinical benefit rate (CBR) where benefit is defined as complete or partial response (CR or PR) or stable disease (SD) ≥24 weeks according to RECIST 1.1 criteria. Additional EPs include safety and tolerability, and the relationship between AR expression and ENZA activity. If the CBR is ≥3 in 21 evaluable pts, the sample size will increase to 66 pts. The primary EP will be analyzed in pts with centrally confirmed AR expression (≥10% nuclear staining by IHC), who have received at least one dose of ENZA, and have ≥1 post-baseline tumor assessment. The null hypothesis (H0), that the true CBR is 10%, will be tested against a 1-sided alternative. This Simon’s two-stage design yields 90% power when the true response rate is 25% with a 1-sided type 1 error rate of 5%. Enrollment is expected to continue through 2016. References: 1. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol. 2011;24(7):924-31. 2. J. Richer, AACR Advances in Breast Cancer, San Diego, CA, October 2013. Citation Format: Maureen E Trudeau, Eric Winer, Joyce L Steinberg, Maggie Liosatos, Srinivasu Poondru, Michael Dydo, Yun Zhou, Michael Westphal, Amy C Peterson, William Gradishar. A phase 2 single-arm study to evaluate the clinical activity, safety and tolerability of enzalutamide (ENZA) with trastuzumab in patients with advanced human growth factor receptor 2 (HER2)-positive breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr OT3-1-06.
Abstract 2979: Association of Aortic Annular Dilatation With Aortic Regurgitation in Patients With Thoracic Aneurysms: The GenTAC Registry
Authors: Kathryn Holmes, Donald Brambilla, Jonathan W Weinsaft, Michael Silberbach, Poyee T Tung, William Ravekes, Craig T Basson, Hal Dietz, Cheryl L Maslen, Howard K Song, Reed E Pyeritz, Barbara Kroner, Kim A Eagle, Richard B Devereux
Journal: Circulation (2009)
Metastatik Ürotelyal Karsinomda Küratif Amaçlı Cerrahi: Alman Deneyimi (AUO AB 3 / 5)
Authors: Jan Lehmann a, Henrik Suttmann, Peter Albers b, Björn Volkmer, Jürgen E. Gschwend, Guido Fechner, Martin Spahn, Axel Heidenreich, Axel Odenthal, Christoph Seif, Nils Nürnberg, Christian Wülfing, Christoph Greb, Tilmann Kälble, Marc-Oliver Grimm, Claus Friedrich Fieseler, Susanne Krege, Margitta Retz, Heiner Schulte-Baukloh, Martin Gerber, Markus Hack, Jörn Kamradt, Michael Stöckle
Journal: European Urology (2009)